Table 1. Baseline demographics and clinical characteristics for all randomly assigned patients.
| Characteristic | NACT+CCRT (n=73) | CCRT (n=73) | χ2 | p-value | |
|---|---|---|---|---|---|
| No. of patients | No. of patients | ||||
| Age (yr) | 51 (35–69) | 53 (30–68) | 0.558 | 0.456 | |
| KPS | 90 (70–100) | 90 (80–100) | 1.077 | 0.331 | |
| Histopathological diagnosis | 1.126 | 0.228 | |||
| Squamous cell carcinoma | 65 (89.0) | 64 (87.7) | |||
| Adenocarcinoma | 6 (8.2) | 6 (8.2) | |||
| Adenosquamous carcinoma | 2 (2.8) | 3 (4.1) | |||
| Disease stage (FIGO 2009) | 1.803 | 0.181 | |||
| II B | 49 (67.1) | 50 (68.5) | |||
| III A | 4 (5.5) | 3 (4.1) | |||
| III B | 18 (24.7) | 19 (26.0) | |||
| IV A | 2 (2.7) | 1 (1.4) | |||
| Disease stage (FIGO 2018) | 2.443 | 0.12 | |||
| II B | 27 (37.0) | 28 (38.4) | |||
| III A | 2 (2.7) | 3 (4.1) | |||
| III B | 14 (19.2) | 13 (17.8) | |||
| III C1r | 28 (38.4) | 27 (37.0) | |||
| IV A | 2 (2.7) | 2 (2.7) | |||
| Maximum diameter of the largest (cm) | 5.1 (4.7–7.4) | 5.2 (4.5–7.3) | 0.729 | 0.395 | |
| Hemoglobin at baseline (g/dL) | 10.2 (7.4–13.6) | 11.7 (7.2–14.1) | 0.974 | 0.621 | |
Values are presented as median (range) or number (%).
CCRT, concurrent chemoradiotherapy; FIGO, International Federation of Gynecology and Obstetrics; KPS, Karnofsky performance score; NACT+CCRT, neoadjuvant chemotherapy combined with concurrent chemoradiotherapy.